Overview

Multidisciplinary Multiple Myeloma Care

Multiple myeloma, also known as myeloma, is a hematologic cancer (or cancer of the blood). Although multiple myeloma is the second most common blood cancer, after non-Hodgkin lymphoma, it is not a common cancer. The American Cancer Society estimates that 30,770 new cases of multiple myeloma will be diagnosed in 2018. Multiple myeloma is more common in men than women, and it occurs more frequently with increasing age, with the greatest incidence in those over age 70.

The main goal of this project is to raise awareness about provider education needs related to this patient population; to establish vetted, designated resources to help fill unmet needs; to help educate the cancer care team on effective practices in caring for patients with multiple myeloma; and to foster a network of engaged community cancer care professionals.

For more information about this project, please contact Maya Sanford, Program Manager, ACCC Provider Education.

 

Featured Publications

Multidisciplinary Multiple Myeloma Care: Models of Quality Improvement
[Oncology Issues]

Alexandra Howson, PHD

The Association of Community Cancer Centers (ACCC) has supported QI initiatives for many years through its Visiting Experts Program. In 2020 ACCC offered QI programs designed to optimize care for patients with multiple myeloma. Via custom workshops, multidisciplinary team members from three cancer programs appraised their own challenges and opportunities to improve care and developed QI plans that were specific, measurable, and actionable over a six-month time frame. The QI time frame included workshop participation, baseline data reporting, progress calls with ACCC, and outcomes evaluation.

Thank you to our Cancer Program Members:

  • CalvertHealth Medical Center, Prince Frederick, MD
  • Central Care Cancer Center, Bolivar, MO
  • Holy Cross Hospital, Silver Spring, MD
 
Multidisciplinary Multiple Myeloma Care: Models of Effective Care Delivery

Multidisciplinary Multiple Myeloma Care: Models of Effective Care Delivery offers a convenient summary of recent updates in the management of this heterogeneous disease, including information on:

  • Diagnostic Criteria by the International Myeloma Working Group
  • Revised International Staging System
  • ASCO Clinical Practice Guideline Update: Role of Bone Modifying Agents in Multiple Myeloma

Plus, read how three cancer programs—a community-based comprehensive program, an academic medical center, and an NCI-designated program—are delivering multidisciplinary care to this patient population.

ACCC thanks the following member programs for their participation:

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
  • Moffitt Cancer Center, Tampa, Florida
  • Yuma Regional Medical Center Cancer Center, Yuma, Arizona
 

Our Partner

Multiple Myeloma Research Foundation

Our Supporter

Amgen Oncology
Funding & support provided by Amgen Oncology